Clinical Trials Logo

Localized Breast Carcinoma clinical trials

View clinical trials related to Localized Breast Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06297265 Not yet recruiting - Clinical trials for Anatomic Stage IA Breast Cancer AJCC v8

Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This phase II trial evaluates manual lymphatic drainage breast massage for reducing treatment-related side effects in women undergoing radiation therapy after breast conserving surgery for breast cancer that has not spread to other parts of the body (localized). Breast conserving surgery can be an effective treatment option for early stage breast cancer, but it can also be associated with side effects including fluid collection in tissues/swelling (lymphedema), pain, reduced quality of life, and poorer body image. Manual lymphatic drainage is a gentle massage technique used to reduce swelling. It may be a safe and effective way to reduce treatment-related side effects in women receiving radiation therapy after surgery for localized breast cancer.

NCT ID: NCT05086731 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer

Start date: October 22, 2021
Phase: N/A
Study type: Interventional

This clinical trial evaluates the feasibility and acceptability of a mobile health device in improving oral chemotherapy adherence in women with triple negative breast cancer that has not spread to other places in the body (non-metastatic). A mobile health device, called SMRxT smart pill bottle may help doctors to remind patients to take medicine on time and monitor their symptoms.

NCT ID: NCT04052555 Active, not recruiting - Clinical trials for Recurrent Breast Carcinoma

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Start date: September 24, 2020
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the best dose of berzosertib when given together with the usual treatment (radiation therapy) in treating patients with triple negative or estrogen receptor and/or progesterone receptor positive, HER-2 negative breast cancer. Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving M6620 and radiation therapy may kill tumor cells more effectively than radiation alone or shrink or stabilize breast cancer for longer than radiation therapy alone.